Meet selectION, Inc. at the BIO International Convention in San Diego, CA, on June 22^nd-25^th, 2026

SAN DIEGO, May 12, 2026 – Meet selectION’s management team for an update on si-544, selectION’s best-in-class Kv1.3 ion channel blocker in development as a disease-modifying treatment for T cell-mediated autoimmune diseases. selectION recently completed Phase 1b clinical trials in patients with atopic dermatitis and psoriasis, demonstrating excellent safety, tolerability, and early efficacy signals. Further details regarding the Company’s clinical progress and planned Phase 2 development strategy will be discussed during partnering sessions.